by Alexandra Grace | Nov 8, 2023
Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. ALS One 5th Annual ALS Research Symposium. Virtual, Oct 6-7, 2022.
by Alexandra Grace | Nov 8, 2023
Benatar M (keynote speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. Expert-in-the-Field speaker at the 10th Annual University of California Irvine Health Neuromuscular Colloquium. Irvine, CA, June, 2022.
by Alexandra Grace | Nov 8, 2023
Benatar M (invited speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. University College London Queen Square Motor Neuron Disease Center Seminar. London, UK, May 2022.
by Alexandra Grace | Nov 8, 2023
Benatar M (invited speaker). The ATLAS Study. MDA Industry Update Webinar. Virtual, February 24, 2022.
by Alexandra Grace | Nov 8, 2023
Benatar M (invited speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. Neuroscience Grand Rounds. University of British Columbia, Vancouver, Canada, Feb 2022.
Recent Comments